Attention Deficit Hyperactivity Disorder
Conditions
Brief summary
The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) of not taking the medication for a maximum of 6 days over a 28-day study treatment period.
Detailed description
The present study is designed to assess the effect of missed doses of daily medication (off-days). On the off-days the patient will take a placebo (sugar pill). Over the 4 weeks of the actual study there will be 6 random off-days of study medicine and neither the caregiver, patient nor study doctor will know which days are the missing days. To cover all aspects of the patients' lives and notably their school time, aside from investigator's assessments, evaluations will also be performed on a daily basis by those involved in their day-to-day life: parents, teachers (on school days) and the patients themselves, using an electronic diary.
Interventions
DRUGPlacebo
Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
DRUGAtomoxetine
25-80 milligrams (mg) administered orally, once daily.
DRUGOsmotic-release oral system methylphenidate
18-54 mg administered orally, once daily.
Sponsors
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Years to 16 Years
Healthy volunteers
No
Inclusion criteria
* Patients must meet the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR) diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD), confirmed at screening by administering the Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version. * Patients must have an Attention-Deficit/Hyperactivity Disorder Rating Scale - IV - Parent Version: Investigator Administered and Scored, total score of less than or equal to 20 at screening and baseline. * Patients must have a Clinical Global Impression-Attention-Deficit/Hyperactivity Disorder-Improvement score of 1 (very much better) or 2 (much better) at screening and baseline. * Patients must have been taking either atomoxetine or osmotic-release oral system methylphenidate for the treatment of ADHD between 3 and a maximum of 15 months prior to screening. * Patients must have been receiving the same dose of atomoxetine or osmotic-release oral system methylphenidate as monotherapy in a single daily dose during the 4 weeks prior to screening. * For females of child-bearing potential only: Test negative for pregnancy at the time of entry based on a urine pregnancy test * Signed informed consent document (ICD)
Exclusion criteria
* Patients who weigh less than 20 kilograms (kg) or more than 70 kg at study entry * Documented history of bipolar disorder, any history of psychosis or pervasive development disorder. * Patients with a history of any seizure disorder or patients who have taken anticonvulsant treatment for seizure control. * Patients at serious suicidal risk. * History of severe allergies to more than one class of medications or have had multiple adverse drug reactions. * Patients with acute or unstable medical conditions including cardiovascular disease and hypertension. * Patients taking excluded concomitant medications or likely to begin structured psychotherapy for ADHD. * Patients who are currently enrolled in, or discontinued within the last 30 days from a clinical trial. * Sexually active females who do not use a medically acceptable method of contraception.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Daily Parent Report of Evening and Morning Behavior-Revised (DPREMB-R) Scale Mean Total Score (On-Days Versus Off-Days) During the 4-Week Treatment Period | Baseline through 4 weeks | Parent-completed 11-item questionnaire; measures difficulty level of and 8 common evening behaviors (such as, sit through dinner) and 3 common morning behaviors (such as, get out of bed). Each item is scored on a 4-point Likert scale ranging from 0 (no difficulty) to 3 (a lot of difficulty). Total score (evening+morning) range is 0 to 33. Higher scores indicate greater difficulty in evening and morning behavior. DPREMB-R total score between days without missing doses (on-days) and days with missing doses (off-days) was not analyzed due to the insufficient sample size. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Global Impression of Perceived Difficulties (GIPD) Scale-Patient Version Total Score and Individual Items (On-Days Versus Off-Days) During the 4-Week Treatment Period | Baseline through 4 weeks | Assesses attention-deficit/hyperactivity disorder (ADHD)-related difficulties (overall difficulties perceived in morning, during school, during homework, in evening, over entire day and night). Participant rates difficulties during past week on 7-point scale (1=normal, not difficult at all; 7=extremely difficult) for each of 5 items. Total score=sum of all subscores (items); range: 5 to 35. Higher scores=greater impairment. GIPD-Pat total score and item scores between days without missing doses (on-days) and days with missing doses (off-days) were not analyzed due to insufficient sample size. |
| Conners' Global Index-Teacher Rating Scale Total Score (On-Days Versus Off-Days) During the 4-Week Treatment Period | Baseline through 4 weeks | The teacher version of Conners' Global Index consists of 10 items with each item being scored on a 4-point scale ranging from 0 (not true at all, or never/seldom) to 3 (very much true, or very often/very frequent). The total score ranges from 0 to 30. Higher scores indicate greater impairment. The Conner's Global Index-Teacher Rating Scale total score between days without missing doses (on-days) and days with missing doses (off-days) was not analyzed due to the insufficient sample size. |
| Global Impression of Perceived Difficulties Scale-Patient Version (GIPD-Pat) Scale Total Score and Individual Items During the 4-Week Treatment Period | Baseline through 4 weeks | Assesses attention-deficit/hyperactivity disorder (ADHD)-related difficulties (overall difficulties perceived in morning, during school, during homework, in evening, over entire day and night). Difficulties during past week are rated by participant on a 7-point scale (1=normal, not difficult at all; 7=extremely difficult) for each of 5 items. Total score=sum of all subscores (items); range: 5 to 35. Higher scores=greater impairment. Mean GIPD-Pat total score and individual item scores for days with missing doses (off-days) between both groups were not analyzed due to insufficient sample size. |
| Attention-Deficit/Hyperactivity Disorder Rating Scale-Parent Version: Investigator Administered and Scored (ADHD-RS-IV Parent:Inv) Total Score and Subscores at Weeks 2, 3, and 4 | Weeks 2, 3, and 4 | Assesses 18 Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) ADHD diagnosis symptoms/severity in past week. Each item: 0 (none/never, rarely) to 3 (severe/very often). Total score ranges from 0 to 54. Higher total scores indicate greater illness severity. This outcome measure was not analyzed due to the insufficient sample size. |
| Clinical Global Impression-Attention Deficit/Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) at Weeks 2, 3, and 4 | Weeks 2, 3, and 4 | This instrument is a single-item expert rating of the severity of the participant's attention-deficit/hyperactivity disorder (ADHD) symptoms in relation to the assessor's total experience of participants with ADHD. Severity is rated on a 7-point scale (1=normal, not ill at all; 7=among the most extremely ill participants). Higher scores represent greater illness severity. This outcome measure was not analyzed due to the insufficient sample size. |
| Emotion Expression Scale for Children (EESC)-Parent Rated Total Score up to Week 5 | Up to Week 5 | 29-item parent-reported measure used to monitor effect of attention-deficit/hyperactivity disorder (ADHD) medication; examines 3 aspects of emotion expression: positive emotions, emotional flatness, and emotional lability. Each item rated on 5-point Likert scale (1=not at all true to 5=very much true). Positive emotional subscale items reversed scored (6-raw score). Total score=transformed positive emotion + emotional flatness+ emotional lability subscales. Total scores range: 29 to 145. Higher scores=emotional impairment. This outcome measure not analyzed due to insufficient sample size. |
| Conners' Global Index-Teacher Rating Scale Total Score During the 4-Week Treatment Period | Baseline through 4 weeks | The teacher version of Conners' Global Index consists of 10 items with each item being scored on a 4-point scale ranging from 0 (not true at all, or never/seldom) to 3 (very much true, or very often/very frequent). The total score ranges from 0 to 30. Higher scores indicate greater impairment. The Conners' Global Index-Teacher Rating Scale total score for days with missing doses (off-days) between both groups were not analyzed due to insufficient sample size. |
| Global Impression of Perceived Difficulties Investigator Version (GIPD-Inv) Total Score and Subscores At Weeks 2, 3, and 4 | Weeks 2, 3, and 4 | Assesses attention-deficit/hyperactivity disorder (ADHD)-related difficulties (overall difficulties perceived in morning, during school, during homework, in evening, and over entire day and night). Difficulties during past week are rated by investigator on a 7-point scale (1=normal, not difficult at all; 7=extremely difficult) for each of 5 items. Total score=sum of all subscores (items) and ranges from 5 to 35. Higher scores indicate greater impairment. This outcome measure was not analyzed due to the insufficient sample size. |
| Daily Parent Report of Evening and Morning Behavior-Revised (DPREMB-R) Scale Subscores (On-Days Versus Off-Days) During the 4-Week Treatment Period | Baseline through 4 weeks | Parent-completed 11-item questionnaire; measures difficulty level of 8 common evening behaviors (such as, sit through dinner) and 3 common morning behaviors (such as, get out of bed) from 0 (no difficulty) to 3 (a lot of difficulty). Evening behavior total score range is 0 to 24. Morning behavior total score range is 0 to 9. Higher scores indicate greater difficulty in evening and morning behavior. DPREMB-R subscores between days without missing doses (on-days) and days with missing doses (off-days) not analyzed due to insufficient sample size. |
| Patient Outcomes Questions (On-Days Versus Off-Days) During the 4-Week Treatment Period | Baseline through 4 weeks | 6-item questionnaire from attention-deficit/hyperactivity disorder (ADHD) advocacy group evaluates treatment outcomes ADHD participant's perspective. Parent completed on each day of on/off period. Each item ranged from 1 (I totally agree) to 5 (I totally disagree). Items 1 and 2 pertain to sleeping and eating; high scores=better outcome. Items 3-6 pertain to behavior; high scores=worse outcome. The mean scores for analysis would have been created for each question across the days of each of the on and off phases; however, mean scores were not analyzed due to insufficient sample size. |
| Daily Parent Report of Evening and Morning Behavior-Revised (DPREMB-R) Scale Total Score and Subscores During the 4-Week Treatment Period | Baseline through 4 weeks | Parent-completed 11-item questionnaire; measures difficulty level of 3 common morning behaviors (such as, get out of bed) and 8 common evening behaviors (such as, sit through dinner) from 0 (no difficulty) to 3 (a lot of difficulty). Evening behavior total score range is 0 to 24. Morning behavior total score range is 0 to 9. Total score (evening+morning) range is 0 to 33. Higher scores indicate greater difficulty in evening and morning behavior. Mean DPREMB-R total score and subscores for days with missing doses (off-days) between both groups were not analyzed due to insufficient sample size. |
Other
| Measure | Time frame |
|---|---|
| Change From Baseline in Heart Rate up to 5 Weeks | Baseline, up to 5 weeks |
| Change From Baseline in Systolic and Diastolic Blood Pressure up to 5 Weeks | Baseline, up to 5 weeks |
Countries
Netherlands, Spain, Sweden
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Atomoxetine Participants received 25-80 milligrams (mg) of atomoxetine orally, once daily for 4 weeks (on/off period), except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. | 15 |
| Osmotic-Release Oral System (OROS) Methylphenidate Participants received 18-54 mg of OROS methylphenidate orally, once daily for 4 weeks (on/off period), except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. | 8 |
| Total | 23 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Entry Criteria Not Met | 1 | 0 |
| Overall Study | Protocol Violation | 0 | 1 |
Baseline characteristics
| Characteristic | Osmotic-Release Oral System (OROS) Methylphenidate | Total | Atomoxetine |
|---|---|---|---|
| Age Continuous | 10.9 years STANDARD_DEVIATION 2.8 | 10.8 years STANDARD_DEVIATION 2.64 | 10.8 years STANDARD_DEVIATION 2.65 |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Current Episode Combined | 4 participants | 11 participants | 7 participants |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Current Episode Hyperactive/Impulsive | 1 participants | 1 participants | 0 participants |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Current Episode Inattentive | 0 participants | 1 participants | 1 participants |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Current Episode Missing | 0 participants | 1 participants | 1 participants |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Current Episode Subtype not present | 3 participants | 9 participants | 6 participants |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Lifetime Episode Combined | 7 participants | 15 participants | 8 participants |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Lifetime Episode Hyperactive/Impulsive | 1 participants | 1 participants | 0 participants |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Lifetime Episode Inattentive | 0 participants | 5 participants | 5 participants |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Lifetime Episode Missing | 0 participants | 1 participants | 1 participants |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Subtype: Lifetime Episode Subtype not present | 0 participants | 1 participants | 1 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 7 Participants | 22 Participants | 15 Participants |
| Region of Enrollment Netherlands | 0 participants | 1 participants | 1 participants |
| Region of Enrollment Spain | 8 participants | 20 participants | 12 participants |
| Region of Enrollment Sweden | 0 participants | 2 participants | 2 participants |
| Sex: Female, Male Female | 2 Participants | 5 Participants | 3 Participants |
| Sex: Female, Male Male | 6 Participants | 18 Participants | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 7 / 15 | 4 / 8 |
| serious Total, serious adverse events | 0 / 15 | 0 / 8 |
Outcome results
Primary
Daily Parent Report of Evening and Morning Behavior-Revised (DPREMB-R) Scale Mean Total Score (On-Days Versus Off-Days) During the 4-Week Treatment Period
Parent-completed 11-item questionnaire; measures difficulty level of and 8 common evening behaviors (such as, sit through dinner) and 3 common morning behaviors (such as, get out of bed). Each item is scored on a 4-point Likert scale ranging from 0 (no difficulty) to 3 (a lot of difficulty). Total score (evening+morning) range is 0 to 33. Higher scores indicate greater difficulty in evening and morning behavior. DPREMB-R total score between days without missing doses (on-days) and days with missing doses (off-days) was not analyzed due to the insufficient sample size.
Time frame: Baseline through 4 weeks
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Attention-Deficit/Hyperactivity Disorder Rating Scale-Parent Version: Investigator Administered and Scored (ADHD-RS-IV Parent:Inv) Total Score and Subscores at Weeks 2, 3, and 4
Assesses 18 Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) ADHD diagnosis symptoms/severity in past week. Each item: 0 (none/never, rarely) to 3 (severe/very often). Total score ranges from 0 to 54. Higher total scores indicate greater illness severity. This outcome measure was not analyzed due to the insufficient sample size.
Time frame: Weeks 2, 3, and 4
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Clinical Global Impression-Attention Deficit/Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) at Weeks 2, 3, and 4
This instrument is a single-item expert rating of the severity of the participant's attention-deficit/hyperactivity disorder (ADHD) symptoms in relation to the assessor's total experience of participants with ADHD. Severity is rated on a 7-point scale (1=normal, not ill at all; 7=among the most extremely ill participants). Higher scores represent greater illness severity. This outcome measure was not analyzed due to the insufficient sample size.
Time frame: Weeks 2, 3, and 4
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Conners' Global Index-Teacher Rating Scale Total Score During the 4-Week Treatment Period
The teacher version of Conners' Global Index consists of 10 items with each item being scored on a 4-point scale ranging from 0 (not true at all, or never/seldom) to 3 (very much true, or very often/very frequent). The total score ranges from 0 to 30. Higher scores indicate greater impairment. The Conners' Global Index-Teacher Rating Scale total score for days with missing doses (off-days) between both groups were not analyzed due to insufficient sample size.
Time frame: Baseline through 4 weeks
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Conners' Global Index-Teacher Rating Scale Total Score (On-Days Versus Off-Days) During the 4-Week Treatment Period
The teacher version of Conners' Global Index consists of 10 items with each item being scored on a 4-point scale ranging from 0 (not true at all, or never/seldom) to 3 (very much true, or very often/very frequent). The total score ranges from 0 to 30. Higher scores indicate greater impairment. The Conner's Global Index-Teacher Rating Scale total score between days without missing doses (on-days) and days with missing doses (off-days) was not analyzed due to the insufficient sample size.
Time frame: Baseline through 4 weeks
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Daily Parent Report of Evening and Morning Behavior-Revised (DPREMB-R) Scale Subscores (On-Days Versus Off-Days) During the 4-Week Treatment Period
Parent-completed 11-item questionnaire; measures difficulty level of 8 common evening behaviors (such as, sit through dinner) and 3 common morning behaviors (such as, get out of bed) from 0 (no difficulty) to 3 (a lot of difficulty). Evening behavior total score range is 0 to 24. Morning behavior total score range is 0 to 9. Higher scores indicate greater difficulty in evening and morning behavior. DPREMB-R subscores between days without missing doses (on-days) and days with missing doses (off-days) not analyzed due to insufficient sample size.
Time frame: Baseline through 4 weeks
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Daily Parent Report of Evening and Morning Behavior-Revised (DPREMB-R) Scale Total Score and Subscores During the 4-Week Treatment Period
Parent-completed 11-item questionnaire; measures difficulty level of 3 common morning behaviors (such as, get out of bed) and 8 common evening behaviors (such as, sit through dinner) from 0 (no difficulty) to 3 (a lot of difficulty). Evening behavior total score range is 0 to 24. Morning behavior total score range is 0 to 9. Total score (evening+morning) range is 0 to 33. Higher scores indicate greater difficulty in evening and morning behavior. Mean DPREMB-R total score and subscores for days with missing doses (off-days) between both groups were not analyzed due to insufficient sample size.
Time frame: Baseline through 4 weeks
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Emotion Expression Scale for Children (EESC)-Parent Rated Total Score up to Week 5
29-item parent-reported measure used to monitor effect of attention-deficit/hyperactivity disorder (ADHD) medication; examines 3 aspects of emotion expression: positive emotions, emotional flatness, and emotional lability. Each item rated on 5-point Likert scale (1=not at all true to 5=very much true). Positive emotional subscale items reversed scored (6-raw score). Total score=transformed positive emotion + emotional flatness+ emotional lability subscales. Total scores range: 29 to 145. Higher scores=emotional impairment. This outcome measure not analyzed due to insufficient sample size.
Time frame: Up to Week 5
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Global Impression of Perceived Difficulties (GIPD) Scale-Patient Version Total Score and Individual Items (On-Days Versus Off-Days) During the 4-Week Treatment Period
Assesses attention-deficit/hyperactivity disorder (ADHD)-related difficulties (overall difficulties perceived in morning, during school, during homework, in evening, over entire day and night). Participant rates difficulties during past week on 7-point scale (1=normal, not difficult at all; 7=extremely difficult) for each of 5 items. Total score=sum of all subscores (items); range: 5 to 35. Higher scores=greater impairment. GIPD-Pat total score and item scores between days without missing doses (on-days) and days with missing doses (off-days) were not analyzed due to insufficient sample size.
Time frame: Baseline through 4 weeks
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Global Impression of Perceived Difficulties Investigator Version (GIPD-Inv) Total Score and Subscores At Weeks 2, 3, and 4
Assesses attention-deficit/hyperactivity disorder (ADHD)-related difficulties (overall difficulties perceived in morning, during school, during homework, in evening, and over entire day and night). Difficulties during past week are rated by investigator on a 7-point scale (1=normal, not difficult at all; 7=extremely difficult) for each of 5 items. Total score=sum of all subscores (items) and ranges from 5 to 35. Higher scores indicate greater impairment. This outcome measure was not analyzed due to the insufficient sample size.
Time frame: Weeks 2, 3, and 4
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Global Impression of Perceived Difficulties Scale-Patient Version (GIPD-Pat) Scale Total Score and Individual Items During the 4-Week Treatment Period
Assesses attention-deficit/hyperactivity disorder (ADHD)-related difficulties (overall difficulties perceived in morning, during school, during homework, in evening, over entire day and night). Difficulties during past week are rated by participant on a 7-point scale (1=normal, not difficult at all; 7=extremely difficult) for each of 5 items. Total score=sum of all subscores (items); range: 5 to 35. Higher scores=greater impairment. Mean GIPD-Pat total score and individual item scores for days with missing doses (off-days) between both groups were not analyzed due to insufficient sample size.
Time frame: Baseline through 4 weeks
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Secondary
Patient Outcomes Questions (On-Days Versus Off-Days) During the 4-Week Treatment Period
6-item questionnaire from attention-deficit/hyperactivity disorder (ADHD) advocacy group evaluates treatment outcomes ADHD participant's perspective. Parent completed on each day of on/off period. Each item ranged from 1 (I totally agree) to 5 (I totally disagree). Items 1 and 2 pertain to sleeping and eating; high scores=better outcome. Items 3-6 pertain to behavior; high scores=worse outcome. The mean scores for analysis would have been created for each question across the days of each of the on and off phases; however, mean scores were not analyzed due to insufficient sample size.
Time frame: Baseline through 4 weeks
Population: No participants had data analyzed due to the termination of the trial and the insufficient sample size.
Other Pre-specified
Change From Baseline in Heart Rate up to 5 Weeks
Time frame: Baseline, up to 5 weeks
Population: Safety population: all participants who entered the study and took at least 1 dose of study medication.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Atomoxetine | Change From Baseline in Heart Rate up to 5 Weeks | -1.2 beats per minute (bpm) | Standard Deviation 7.65 |
| Osmotic-Release Oral System (OROS) Methylphenidate | Change From Baseline in Heart Rate up to 5 Weeks | 2.5 beats per minute (bpm) | Standard Deviation 12.74 |
Other Pre-specified
Change From Baseline in Systolic and Diastolic Blood Pressure up to 5 Weeks
Time frame: Baseline, up to 5 weeks
Population: Safety population: all participants who entered the study and took at least 1 dose of study medication.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Atomoxetine | Change From Baseline in Systolic and Diastolic Blood Pressure up to 5 Weeks | Diastolic Blood Pressure | 1.9 millimeters of mercury (mm Hg) | Standard Deviation 6.14 |
| Atomoxetine | Change From Baseline in Systolic and Diastolic Blood Pressure up to 5 Weeks | Systolic Blood Pressure | -0.1 millimeters of mercury (mm Hg) | Standard Deviation 9 |
| Osmotic-Release Oral System (OROS) Methylphenidate | Change From Baseline in Systolic and Diastolic Blood Pressure up to 5 Weeks | Diastolic Blood Pressure | -1.5 millimeters of mercury (mm Hg) | Standard Deviation 4.67 |
| Osmotic-Release Oral System (OROS) Methylphenidate | Change From Baseline in Systolic and Diastolic Blood Pressure up to 5 Weeks | Systolic Blood Pressure | -3.7 millimeters of mercury (mm Hg) | Standard Deviation 3.75 |